Logo image of PLUR

PLURI INC (PLUR) Stock Fundamental Analysis

NASDAQ:PLUR - Nasdaq - US72942G2030 - Common Stock - Currency: USD

4.33  -0.21 (-4.63%)

Fundamental Rating

2

PLUR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of PLUR have multiple concerns. While showing a medium growth rate, PLUR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year PLUR has reported negative net income.
PLUR had a negative operating cash flow in the past year.
PLUR had negative earnings in each of the past 5 years.
In the past 5 years PLUR always reported negative operating cash flow.
PLUR Yearly Net Income VS EBIT VS OCF VS FCFPLUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -64.35%, PLUR is not doing good in the industry: 61.99% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -64.35%
ROE N/A
ROIC N/A
ROA(3y)-56.83%
ROA(5y)-53.66%
ROE(3y)-7370.79%
ROE(5y)-4450.32%
ROIC(3y)N/A
ROIC(5y)N/A
PLUR Yearly ROA, ROE, ROICPLUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

PLUR's Gross Margin of 47.49% is fine compared to the rest of the industry. PLUR outperforms 77.62% of its industry peers.
In the last couple of years the Gross Margin of PLUR has remained more or less at the same level.
PLUR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.51%
PLUR Yearly Profit, Operating, Gross MarginsPLUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

2

2. Health

2.1 Basic Checks

PLUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLUR has more shares outstanding
The number of shares outstanding for PLUR has been increased compared to 5 years ago.
The debt/assets ratio for PLUR is higher compared to a year ago.
PLUR Yearly Shares OutstandingPLUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PLUR Yearly Total Debt VS Total AssetsPLUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

PLUR has an Altman-Z score of -20.61. This is a bad value and indicates that PLUR is not financially healthy and even has some risk of bankruptcy.
PLUR's Altman-Z score of -20.61 is on the low side compared to the rest of the industry. PLUR is outperformed by 86.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.61
ROIC/WACCN/A
WACC8.31%
PLUR Yearly LT Debt VS Equity VS FCFPLUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 5.04 indicates that PLUR has no problem at all paying its short term obligations.
PLUR has a Current ratio of 5.04. This is comparable to the rest of the industry: PLUR outperforms 54.00% of its industry peers.
A Quick Ratio of 5.04 indicates that PLUR has no problem at all paying its short term obligations.
PLUR has a Quick ratio of 5.04. This is comparable to the rest of the industry: PLUR outperforms 55.24% of its industry peers.
Industry RankSector Rank
Current Ratio 5.04
Quick Ratio 5.04
PLUR Yearly Current Assets VS Current LiabilitesPLUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

4

3. Growth

3.1 Past

PLUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.93%, which is quite impressive.
PLUR shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.92%.
The Revenue has been growing by 43.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.37%
Revenue 1Y (TTM)89.92%
Revenue growth 3YN/A
Revenue growth 5Y43.27%
Sales Q2Q%76.19%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLUR Yearly Revenue VS EstimatesPLUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
PLUR Yearly EPS VS EstimatesPLUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

0

4. Valuation

4.1 Price/Earnings Ratio

PLUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLUR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLUR Price Earnings VS Forward Price EarningsPLUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLUR Per share dataPLUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

PLUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PLURI INC

NASDAQ:PLUR (2/21/2025, 8:00:01 PM)

4.33

-0.21 (-4.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10
Earnings (Next)05-07 2025-05-07
Inst Owners10.42%
Inst Owner Change-23.6%
Ins Owners10.49%
Ins Owner Change1.55%
Market Cap30.31M
Analysts82.86
Price TargetN/A
Short Float %0.76%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44.71
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.68
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.1
BVpS-1.15
TBVpS-1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.49%
FCFM N/A
ROA(3y)-56.83%
ROA(5y)-53.66%
ROE(3y)-7370.79%
ROE(5y)-4450.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.51%
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.31%
Cap/Sales 61.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.04
Quick Ratio 5.04
Altman-Z -20.61
F-Score2
WACC8.31%
ROIC/WACCN/A
Cap/Depr(3y)75.54%
Cap/Depr(5y)54.21%
Cap/Sales(3y)103.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.37%
EPS Next Y91.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)89.92%
Revenue growth 3YN/A
Revenue growth 5Y43.27%
Sales Q2Q%76.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.78%
OCF growth 3YN/A
OCF growth 5YN/A